Cash flow remains volatile and disconnected from earnings, highlighted by a 2026Q3 OCF/NI ratio of -0.62 and erratic free cash flow margins that peaked at 10.0% in 2025Q3.
| Cash from Operations | 50.18M | 32.87M | -36.9M | -36.9M | 27.3M | -7.55M | 43.83M | 25.91M |
| Operating CF Margin % | - | 3.85% | -4.83% | -5.36% | 3.91% | -1.18% | 7.73% | 5.56% |
| Operating CF Growth % | 602.73% | 189.07% | 0% | -235.15% | 461.71% | -117.22% | 69.18% | - |
| Net Income | -22.2M | -35.34M | -23.22M | -23.22M | -6.52M | -43.99M | 25.77M | 19.07M |
| Depreciation & Amortization | 20.11M | 19.51M | 18.95M | 18.95M | 14.35M | 13.35M | 11.29M | 9M |
| Stock-Based Compensation | 7.19M | 7.62M | 6.83M | 6.83M | 3.74M | 47.05M | 543K | 727K |
| Deferred Taxes | 555K | 1.3M | 1.22M | 1.22M | 0 | 0 | 3.17M | 3.55M |
| Other Non-Cash Items | 44.45M | 24.54M | 11.46M | 11.46M | 23.13M | -21.37M | 9.39M | 3.56M |
| Working Capital Changes | 1.84M | 15.23M | -52.15M | -52.15M | -7.4M | -2.59M | -6.33M | -9.99M |
| Change in Receivables | 4.32M | 11.22M | -30.33M | -33.4M | -9.51M | 5.88M | -1.2M | 1.13M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -4.12M | -7.92M |
| Change in Payables | 40.68M | 20.43M | 1.37M | 1.37M | 0 | 0 | -1.01M | 9.36M |
| Cash from Investing | -3.12M | -5.55M | -26.37M | -26.37M | -40.24M | -19.54M | -11.69M | -52.48M |
| Capital Expenditures | -11.39M | -6.26M | -7.91M | -7.91M | -38.24M | -17.54M | -11.84M | -14.49M |
| CapEx % of Revenue | 1.2% | 0.73% | 1.04% | 1.15% | 5.47% | 2.75% | 2.09% | 3.11% |
| Acquisitions | 0 | -3.52M | -19.07M | -19.07M | 0 | 0 | 169K | -36.49M |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 10.02M | 0 | 0 | 0 | -2M | -2M | 1.3M | -37.99M |
| Cash from Financing | -8.51M | -19.08M | -7.03M | -7.03M | -6.32M | 116.22M | 21.23M | 37.35M |
| Debt Issued (Net) | -8.22M | -9.91M | -8.43M | -8.43M | -6.32M | -139.45M | 21.23M | 115.81M |
| Equity Issued (Net) | 2.08M | -7.32M | -179K | -179K | 0 | -77.6M | 0 | 277K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | -9.5M | 0 | -66.51M |
| Share Repurchases | -1.09M | -7.32M | -179K | -179K | 0 | -77.6M | 0 | -193K |
| Other Financing | -2.37M | -1.85M | 1.58M | 1.58M | 0 | 342.77M | 0 | -12.24M |
| Net Change in Cash | 26.13M | 8.23M | -70.31M | -70.31M | -19.25M | 89.14M | 53.37M | 10.77M |
| Free Cash Flow | 38.79M | 26.6M | -44.81M | -44.81M | -10.94M | -25.09M | 31.98M | 11.42M |
| FCF Margin % | 4.1% | 3.12% | -5.87% | -6.51% | -1.57% | -3.93% | 5.64% | 2.45% |
| FCF Growth % | 142.59% | 159.37% | 0% | -309.77% | 56.41% | -178.44% | 180.07% | - |
| FCF per Share | 0.29 | 0.20 | -0.33 | -0.33 | -0.08 | -0.19 | 0.24 | 0.09 |
| FCF Conversion (FCF/Net Income) | -1.75x | -1.08x | 1.73x | 0.91x | -4.19x | 0.17x | 1.67x | 1.32x |
| Interest Paid | 2.23M | 4.35M | 4.06M | 4.06M | 1.47M | 18.03M | 11.55M | 8.84M |
| Taxes Paid | 0 | 1K | 4.45M | 4.45M | 0 | 0 | 4.75M | 4.53M |
Regulatory enrollment freeze vulnerability
As reported in recent financial statements, InnovAge's operating cash flow frequently diverges from net income, evidenced by a 2026Q3 OCF/NI ratio of -0.62, which suggests that reported earnings are significantly impacted by non-cash items and working capital fluctuations rather than pure operational cash generation.
The persistent gap between net income and operating cash flow indicates that the company's profitability is heavily influenced by accounting adjustments. Investors should monitor whether this divergence reflects legitimate timing differences in medical claims or a more structural inability to convert service delivery into actual cash inflows.
Based on the provided cash flow data, free cash flow margins have exhibited extreme volatility, swinging from a -4.7% margin in 2025Q1 to a 10.0% peak in 2025Q3, which highlights the difficulty in maintaining consistent cash generation amidst ongoing operational and regulatory recovery efforts.
The inconsistency in free cash flow suggests that the business model remains highly sensitive to quarterly fluctuations in medical care costs and administrative overhead. This lack of a stable FCF trajectory complicates the assessment of the company's long-term ability to self-fund its capital-intensive PACE center expansion.
According to recent SEC filings, InnovAge maintains a disciplined approach to capital expenditure, with CapEx/Revenue ratios consistently remaining below 2.0% over the last ten quarters, suggesting that the company is currently prioritizing operational stabilization over aggressive new facility construction or major infrastructure upgrades.
While low capital intensity may appear favorable, it may also indicate that the company is not sufficiently investing in the modernization of its physical PACE centers. Analysts should investigate whether this level of spending is adequate to maintain the high-touch clinical environment required for long-term participant retention.
As indicated by the quarterly cash flow data, working capital changes have been a primary driver of cash flow variability, with a notable $12.8M inflow in 2026Q3 following a $13.4M outflow in 2026Q1, reflecting the inherent complexity of managing capitated payment cycles and medical claim liabilities.
These significant swings in working capital suggest that the company's cash position is highly susceptible to the timing of government reimbursements and the settlement of third-party provider claims. Such volatility warrants further investigation into the company's internal controls over medical cost accruals and accounts receivable management.
Based on reported figures, stock-based compensation has remained a consistent cash-equivalent expense, averaging roughly $1.8M per quarter, which effectively reduces the true cash available to shareholders despite the company's stated focus on operational turnaround and cost management across its clinical service network.
The consistent use of stock-based compensation, when viewed alongside the company's net losses, suggests that management is utilizing equity to preserve cash. This practice may mask the true cost of talent acquisition and retention in a competitive healthcare labor market, potentially understating the company's actual cash burn.
Quick answers to the most common questions about buying INNV stock.
InnovAge Holding Corp. (INNV) generated $32.9M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
InnovAge Holding Corp. (INNV) generated $26.6M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
InnovAge Holding Corp. (INNV) spent $6.3M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, InnovAge Holding Corp. (INNV) spent $7.3M on share repurchases. This shows the company's commitment to returning capital to its equity investors.